Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734721 | SCV000862885 | uncertain significance | not provided | 2018-08-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001312383 | SCV001502835 | likely benign | Bifunctional peroxisomal enzyme deficiency; Perrault syndrome | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000734721 | SCV001826351 | likely benign | not provided | 2020-11-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002535390 | SCV003676791 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.1278A>T (p.E426D) alteration is located in exon 15 (coding exon 15) of the HSD17B4 gene. This alteration results from a A to T substitution at nucleotide position 1278, causing the glutamic acid (E) at amino acid position 426 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004735790 | SCV005356441 | uncertain significance | HSD17B4-related disorder | 2024-05-24 | no assertion criteria provided | clinical testing | The HSD17B4 c.1278A>T variant is predicted to result in the amino acid substitution p.Glu426Asp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.11% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |